Package Leaflet: Information for the user. Simponi 100 mg solution for injection in pre-filled pen golimumab

Size: px
Start display at page:

Download "Package Leaflet: Information for the user. Simponi 100 mg solution for injection in pre-filled pen golimumab"

Transcription

1 Package Leaflet: Information for the user Simponi 100 mg solution for injection in pre-filled pen golimumab Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. Your doctor will also give you a Patient Alert Card, which contains important safety information you need to be aware of before and during your treatment with Simponi. What is in this leaflet 1. What Simponi is and what it is used for 2. What you need to know before you use Simponi 3. How to use Simponi 4. Possible side effects 5. How to store Simponi 6. Contents of the pack and other information 1. What Simponi is and what it is used for Simponi contains the active substance called golimumab. Simponi belongs to a group of medicines called TNF blockers. It is used in adults for the treatment of the following inflammatory diseases: Rheumatoid arthritis Psoriatic arthritis Axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis Ulcerative colitis Simponi works by blocking the action of a protein called tumour necrosis factor alpha (TNF-α). This protein is involved in inflammatory processes of the body, and blocking it can reduce the inflammation in your body. Rheumatoid arthritis Rheumatoid arthritis is an inflammatory disease of the joints. If you have active rheumatoid arthritis you will first be given other medicines. If you do not respond well enough to these medicines, you may be given Simponi which you will take in combination with another medicine called methotrexate to: Reduce the signs and symptoms of your disease. Slow down the damage to your bones and joints. Improve your physical function.

2 Psoriatic arthritis Psoriatic arthritis is an inflammatory disease of the joints, usually accompanied by psoriasis, an inflammatory disease of the skin. If you have active psoriatic arthritis you will first be given other medicines. If you do not respond well enough to these medicines, you may be given Simponi to: Reduce the signs and symptoms of your disease. Slow down the damage to your bones and joints. Improve your physical function. Ankylosing spondylitis and non-radiographic axial spondyloarthritis Ankylosing spondylitis and non-radiographic axial spondyloarthritis are inflammatory diseases of the spine. If you have ankylosing spondylitis or non-radiographic axial spondyloarthritis, you will first be given other medicines. If you do not respond well enough to these medicines, you may be given Simponi to: Reduce the signs and symptoms of your disease. Improve your physical function. Ulcerative colitis Ulcerative colitis is an inflammatory disease of the bowel. If you have ulcerative colitis you will first be given other medicines. If you do not respond well enough to these medicines, you will be given Simponi to treat your disease. 2. What you need to know before you use Simponi Do not use Simponi: If you are allergic (hypersensitive) to golimumab or any of the other ingredients of this medicine (listed in Section 6). If you have tuberculosis (TB) or any other severe infection. If you have moderate or severe heart failure. If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before using Simponi. Warnings and precautions Talk to your doctor, pharmacist or nurse before using Simponi. Infections Tell your doctor straight away if you already have or get any symptoms of infection, during or after your treatment with Simponi. Symptoms of infection include fever, cough, shortness of breath, flu-like symptoms, diarrhoea, wounds, dental problems or a burning feeling when urinating. You may get infections more easily while using Simponi. Infections may progress more rapidly and may be more severe. In addition, some previous infections may reappear. Tuberculosis (TB) Tell your doctor straight away if symptoms of TB appear during or after your treatment. Symptoms of TB include persistent cough, weight loss, tiredness, fever or night sweats. Cases of TB have been reported in patients treated with Simponi, in rare occasions even in patients who have been treated with medicines for TB. Your doctor will test you to see if you have TB. Your doctor will record these tests on your Patient Alert Card. It is very important that you tell your doctor if you have ever had TB, or if you have been in close contact with someone who has had or has TB. If your doctor feels that you are at risk of TB, you may be treated with medicines for TB before you begin using Simponi.

3 Hepatitis B virus (HBV) Tell your doctor if you are a carrier or if you have or have had HBV before you are given Simponi. Tell your doctor if you think you might be at risk of contracting HBV Your doctor should test you for HBV Treatment with TNF blockers such as Simponi may result in reactivation of HBV in patients who carry this virus, which can be life-threatening in some cases. Invasive fungal infections If you have lived in or travelled to an area where infections caused by specific type of fungi that can affect the lungs or other parts of the body (called histoplasmosis, coccidioidomycosis, or blastomycosis), are common, tell your doctor straight away. Ask your doctor if you don t know if these fungal infections are common in the area in which you have lived or travelled. Cancer and lymphoma Tell your doctor if you have ever been diagnosed with lymphoma (a type of blood cancer) or any other cancer before you use Simponi. If you use Simponi or other TNF blockers, your risk for developing lymphoma or another cancer may increase. Patients with severe rheumatoid arthritis and other inflammatory diseases, who have had the disease for a long time, may be at higher than average risk of developing lymphoma. There have been cases of cancers, including unusual types, in children and teenage patients taking TNF-blocking agents, which sometimes resulted in death. On rare occasions, a specific and severe type of lymphoma called hepatosplenic T-cell lymphoma has been observed in patients taking other TNF-blockers. Most of these patients were adolescent or young adult males. This type of cancer has usually resulted in death. Almost all of these patients had also received medicines known as azathioprine or 6-mercaptopurine. Tell your doctor if you are taking azathioprine or 6-mercaptopurine with Simponi. Patients with severe persistent asthma, chronic obstructive pulmonary disease (COPD), or are heavy smokers may be at increased risk for cancer with Simponi treatment. If you have severe persistent asthma, COPD or are a heavy smoker, you should discuss with your doctor whether treatment with a TNF blocker is appropriate for you. Some patients treated with golimumab have developed certain kinds of skin cancer. If any changes in the appearance of the skin or growths on the skin occur during or after therapy, tell your doctor. Heart failure Tell your doctor straight away if you get new or worsening symptoms of heart failure. Symptoms of heart failure include shortness of breath or swelling of your feet. New and worsening congestive heart failure has been reported with TNF blockers, including Simponi. Some of these patients died. If you have mild heart failure and you are being treated with Simponi, you must be closely monitored by your doctor. Nervous system disease Tell your doctor straight away if you have ever been diagnosed with or develop symptoms of a demyelinating disease such as multiple sclerosis. Symptoms may include changes in your vision, weakness in your arms or legs or numbness or tingling in any part of your body. Your doctor will decide if you should receive Simponi. Operations or dental procedures Talk to your doctor if you are going to have any operations or dental procedures.

4 Tell your surgeon or dentist performing the procedure that you are having treatment with Simponi by showing them your Patient Alert Card. Autoimmune disease Tell your doctor if you develop symptoms of a disease called lupus. Symptoms include persistent rash, fever, joint pain and tiredness. On rare occasions, people treated with TNF blockers have developed lupus. Blood disease In some patients the body may fail to produce enough of the blood cells that help your body fight infections or help you to stop bleeding. If you develop a fever that does not go away, bruise or bleed very easily or look very pale, call your doctor right away. Your doctor may decide to stop treatment. If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Simponi. Vaccinations Talk to your doctor if you have had, or are due to have a vaccine. You should not receive certain (live) vaccines while using Simponi. Certain vaccinations may cause infections. If you received Simponi while you were pregnant, your baby may be at higher risk for getting such an infection for up to approximately six months after the last dose you received during pregnancy. It is important that you tell your baby's doctors and other health care professionals about your Simponi use so they can decide when your baby should receive any vaccine. Therapeutic infectious agents Talk to your doctor if you have recently received or are scheduled to receive treatment with a therapeutic infectious agent (such as BCG instillation used for the treatment of cancer). Allergic reactions Tell your doctor straight away if you develop symptoms of an allergic reaction after your treatment with Simponi. Symptoms of an allergic reaction may include swelling of the face, lips, mouth or throat which may cause difficulty in swallowing or breathing, skin rash, hives, swelling of the hands, feet or ankles. Some of these reactions may be serious or, rarely, life-threatening. Some of these reactions occurred after the first administration of Simponi. Children and adolescents Simponi 100 mg is not recommended for children and adolescents (younger than 18 years). Other medicines and Simponi Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines, including any other medicines to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, or ulcerative colitis. You should not take Simponi with medicines containing the active substance anakinra or abatacept. These medicines are used for the treatment of rheumatic diseases. Tell your doctor or pharmacist if you are taking any other medicines that affect your immune system. You should not receive certain (live) vaccines while using Simponi. If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Simponi.

5 Pregnancy and breast-feeding Talk to your doctor before using Simponi if: You are pregnant or are planning to become pregnant while using Simponi. The effects of this medicine in pregnant women are not known. The use of Simponi in pregnant women is not recommended. If you are being treated with Simponi, you must avoid becoming pregnant by using adequate contraception during your treatment and for at least 6 months after the last Simponi injection. Before starting breast-feeding, your last treatment with Simponi must be at least 6 months ago. You must stop breast-feeding if you are to be given Simponi. If you received Simponi during your pregnancy, your baby may have a higher risk for getting an infection. It is important that you tell your baby s doctors and other health care professionals about your Simponi use before the baby receives any vaccine (for more information see section on vaccination). If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines Simponi may have a minor influence on your ability to drive and use tools or machines. Dizziness may occur after you take Simponi. If this happens, do not drive or use any tools or machines. Simponi contains latex and sorbitol Latex sensitivity A part of the pre-filled pen, the needle cover, contains latex. Because latex may cause severe allergic reactions, talk to your doctor before using Simponi if you or your carer are allergic to latex. Sorbitol intolerance Simponi contains sorbitol (E420). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. 3. How to use Simponi Always use this medicine exactly as your doctor or pharmacist has told you. You should check with your doctor or pharmacist if you are not sure. How much Simponi is given Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis: The recommended dose is 50 mg given once a month, on the same date each month. Talk to your doctor before taking your fourth dose. Your doctor will determine if you should continue Simponi treatment. o If you weigh more than 100 kg, the dose might be increased to 100 mg (the content of 1 pre-filled pen) given once a month, on the same date each month. Ulcerative colitis The table below shows how you will usually use this medicine.

6 Initial treatment A starting dose of 200 mg (the contents of 2 pre-filled pens) followed by 100 mg (the contents of 1 pre-filled pen) 2 weeks later. Maintenance treatment In patients weighing less than 80 kg, 50 mg (the 50 mg pre-filled pen or pre-filled syringe must be used to administer this dose) 4 weeks after your last treatment, then every 4 weeks thereafter. In patients weighing 80 kg or more, 100 mg (the contents of 1 pre-filled pen) 4 weeks after your last treatment, then every 4 weeks thereafter. How Simponi is given Simponi is given by injection under the skin (subcutaneously). At the start, your doctor or nurse may inject Simponi. However, you and your doctor may decide that you may inject Simponi yourself. In this case you will get training on how to inject Simponi yourself. Talk to your doctor if you have any questions about giving yourself an injection. You will find detailed Instructions for administration at the end of this leaflet. If you use more Simponi than you should If you have used or been given too much Simponi (either by injecting too much on a single occasion, or by using it too often), talk to your doctor or pharmacist straight away. Always take the outer carton and this leaflet with you, even if it is empty. If you forget to use Simponi If you forget to use Simponi on your planned date, inject the forgotten dose as soon as you remember. Do not use a double dose to make up for a forgotten dose. When to inject your next dose: If you are less than 2 weeks late, inject the forgotten dose as soon as you remember and stay on your original schedule. If you are more than 2 weeks late, inject the forgotten dose as soon as you remember and talk to your doctor or pharmacist to ask when you need to take the next dose. If you are not sure what to do, talk to your doctor or pharmacist. If you stop using Simponi If you are considering stopping Simponi, talk to your doctor or pharmacist first. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. Some patients may experience serious side effects and may require treatment. The risk of certain side effects is greater with the 100 mg dose compared with the 50 mg dose. Side effects may appear up to several months after the last injection. Tell your doctor straight away if you notice any of the following serious side effects of Simponi which include: allergic reactions which may be serious, or rarely, life-threatening (rare). Symptoms of an allergic reaction may include swelling of the face, lips, mouth or throat which may cause difficulty in swallowing or breathing, skin rash, hives, swelling of the hands, feet or ankles. Some of these reactions occurred after the first administration of Simponi.

7 serious infections (including TB, bacterial infections including serious blood infections and pneumonia, severe fungal infections and other opportunistic infections) (common). Symptoms of an infection can include fever, tiredness, (persistent) cough, shortness of breath, flu-like symptoms, weight loss, night sweats, diarrhoea, wounds, dental problems and a burning feeling when urinating. reactivation of hepatitis B virus if you are a carrier or have had hepatitis B before (rare). Symptoms can include yellowing of the skin and eyes, dark brown-coloured urine, right-sided abdominal pain, fever, feeling sick, being sick, and feeling very tired. nervous system disease such as multiple sclerosis (rare). Symptoms of nervous system disease can include changes in your vision, weakness in your arms or legs, numbness or tingling in any part of your body. cancer of the lymph nodes (lymphoma) (rare). Symptoms of lymphoma can include swelling of the lymph nodes, weight loss, or fever. heart failure (rare). Symptoms of heart failure can include shortness of breath or swelling of your feet. signs of immune system disorders called: - lupus (rare). Symptoms can include joint pain or a rash on cheeks or arms that is sensitive to the sun. - sarcoidosis (rare). Symptoms can include a persistent cough, being short of breath, chest pain, fever, swelling of your lymph nodes, weight loss, skin rashes, and blurred vision. swelling of small blood vessels (vasculitis) (rare). Symptoms can include fever, headache, weight loss, night sweats, rash, and nerve problems such as numbness and tingling. skin cancer (uncommon). Symptoms of skin cancer can include changes in the appearance of your skin or growths on your skin. blood disease (common). Symptoms of blood disease can include a fever that does not go away, bruising or bleeding very easily or looking very pale. blood cancer (leukaemia) (rare). Symptoms of leukaemia can include fever, feeling tired, frequent infections, easy bruising, and night sweats. Tell your doctor straight away if you notice any of the above symptoms. The following additional side effects have been observed with Simponi: Very common side effects (may affect more than 1 in 10 people): Upper respiratory tract infections, sore throat or hoarseness, runny nose Common side effects (may affect up to 1 in 10 people): Abnormal liver tests (increased liver enzymes) found during blood tests done by your doctor Feeling dizzy Headache Feeling numb or having a tingling feeling Superficial fungal infections Abscess Bacterial infections (such as cellulitis) Low red blood cell counts Low white blood cell counts Positive blood lupus test Allergic reactions Indigestion Stomach pain Feeling sick (nausea) Flu Bronchitis Sinus infection Cold sores

8 High blood pressure Fever Asthma, shortness of breath, wheezing Stomach and bowel disorders which include inflammation of the stomach lining and colon which may cause fever Pain and ulcers in the mouth Injection site reactions (including redness, hardness, pain, bruising, itching, tingling and irritation) Hair loss Rash and itching of the skin Difficulty sleeping Depression Feeling weak Bone fractures Chest discomfort Uncommon side effects (may affect up to 1 in 100 people): Kidney infection Cancers, including skin cancer and non-cancerous growths or lumps, including skin moles Skin blisters Psoriasis (including on the palms of your hand and/or the soles of your feet and/or in the form of skin blisters) Low platelet count Combined low platelet, red, and white blood cell count Thyroid disorders Increase in blood sugar levels Increase in blood cholesterol levels Balance disorders Vision disturbances Sensation of heart beating irregularly Narrowing of the blood vessels in the heart Blood clots Flushing Constipation Chronic inflammatory condition of the lungs Acid reflux Gall stones Liver disorders Breast disorders Menstrual disorders Rare side effects (may affect up to 1 in 1,000 people): Failure of the bone marrow to produce blood cells Severely decreased number of white blood cells Infection of the joints or the tissue around them Impaired healing Inflammation of blood vessels in internal organs Leukaemia Melanoma (a type of skin cancer) Merkel cell carcinoma (a type of skin cancer) Scaly, peeling skin

9 Immune disorders that could affect the lungs, skin and lymph nodes (most commonly presenting as sarcoidosis) Pain and discoloration in the fingers or toes Taste disturbances Bladder disorders Kidney disorders Inflammation of the blood vessels in your skin which results in rash Side effects of which the frequency is not known: A rare blood cancer affecting mostly young people (hepatosplenic T-cell lymphoma) Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine. United Kingdom: Yellow Card Scheme at: or search for MHRA Yellow Card in the Google Play or Apple App Store. Ireland: HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: ; Fax: Website: medsafety@hpra.ie Malta: ADR Reporting at: 5. How to store Simponi Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label and the carton after EXP. The expiry date refers to the last day of that month. Store in a refrigerator (2 C-8 C). Do not freeze. Keep the pre-filled pen in the outer carton in order to protect it from light. Do not use this medicine if you notice that the liquid is not a clear to light yellow colour, cloudy, or contains foreign particles. Do not throw away any medicines via wastewater or household waste. Ask your doctor or pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. 6. Contents of the pack and other information What Simponi contains The active substance is golimumab. One 1 ml pre-filled pen contains 100 mg of golimumab. The other ingredients are sorbitol (E420), L-histidine, L-histidine monohydrochloride monohydrate, polysorbate 80 and water for injections. What Simponi looks like and contents of the pack Simponi is supplied as solution for injection in a single-use pre-filled pen. Simponi is available in packs containing 1 pre-filled pen and multipacks containing 3 (3 packs of 1) pre-filled pens. Not all pack sizes may be marketed. The solution is clear to slightly opalescent (having a pearl-like shine), colourless to light yellow and may contain a few small translucent or white particles of protein. Do not use Simponi if the solution is discoloured, cloudy or you can see foreign particles in it.

10 Marketing Authorisation Holder and Manufacturer Janssen Biologics B.V. Einsteinweg CB Leiden The Netherlands For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0) Malta Merck Sharp & Dohme Cyprus Limited Tel: ( ) United Kingdom Merck Sharp & Dohme Limited Tel: +44 (0) This leaflet was last revised in March Detailed information on this medicine is available on the European Medicines Agency web site: PIL.SIM.100.PFP.18.UK.6264.II-078

11 INSTRUCTIONS FOR ADMINISTRATION If you would like to self inject Simponi, you must be trained by a healthcare professional to prepare an injection and give it to yourself. If you have not been trained, please contact your doctor, nurse or pharmacist to schedule a training session. In these instructions: 1. Preparing for use of the pre-filled pen 2. Choosing and preparing the injection site 3. Injecting the medicine 4. After the injection The diagram below (see figure 1) shows what the SmartJect pre-filled pen looks like. 1. Preparing for use of the pre-filled pen Figure 1 Do not shake the pre-filled pen at any time. Do not remove the cap from the pre-filled pen until immediately before the injection. Check the number of pre-filled pens Check the pre-filled pens to make sure the number of pre-filled pens and strength is correct o o If your dose is 100 mg, you will get one 100 mg pre-filled pen If your dose is 200 mg, you will get two 100 mg pre-filled pens and you will need to give yourself two injections. Choose different sites for these injections and give the injections one right after the other. Check expiry date Check the expiration date (as indicated as EXP ) on the pre-filled pen. You can also check the expiration date printed on the carton. Do not use the pre-filled pen if the expiration date has passed. The expiration date refers to the last day of the month. Please contact your doctor or pharmacist for assistance.

12 Check security seal Check the security seal around the cap of the pre-filled pen. Do not use the pre-filled pen if the seal is broken. Please contact your doctor or pharmacist. Wait 30 minutes to allow pre-filled pen to reach room temperature To ensure proper injection, allow the pre-filled pen to sit at room temperature outside the box for 30 minutes out of the reach of children. Do not warm the pre-filled pen in any other way (for example, do not warm it in a microwave or in hot water). Do not remove the pre-filled pen s cap while allowing it to reach room temperature. Get the rest of your equipment ready While you are waiting you can get the rest of your equipment ready, including an alcohol swab, a cotton ball or gauze and a sharps container. Check the liquid in the pre-filled pen Look through the viewing window to make sure that the liquid in the pre-filled pen is clear to slightly opalescent (having a pearl-like shine) and colourless to light yellow. The solution can be used if it contains a few small translucent or white particles of protein. You will also notice an air bubble, which is normal. Do not use the pre-filled pen if the liquid is the wrong colour, cloudy, or contains larger particles. If this happens, talk to your doctor or pharmacist. 2. Choosing and preparing the injection site (see figure 2) You usually inject the medicine into the front of the middle thighs. You can also use the stomach (abdomen) below the belly button, except for approximately the 5 cm area directly underneath the belly button. Do not inject into areas where the skin is tender, bruised, red, scaly, hard or has scars or stretch marks. If multiple injections are required for a single administration, the injections should be administered at different sites on the body. Figure 2 Injection site selection for caregivers if you are not administering the injection yourself (see figure 3) If a caregiver is giving you the injection, they can also use the outer area of the upper arms Again, all sites mentioned can be used regardless of your body type or size.

13 Figure 3 Preparing injection site Wash your hands thoroughly with soap and warm water. Wipe the injection site with an alcohol swab. Allow the skin to dry before injecting. Do not fan or blow on the clean area. Do not touch this area again before giving the injection. 3. Injecting the medicine The cap should not be removed until you are ready to inject the medicine. The medicine should be injected within 5 minutes after the cap has been removed. Remove the cap (figure 4) When you are ready to inject, twist the cap slightly to break the security seal. Pull the cap off and throw it away after your injection. Do not put the cap back on because it may damage the needle inside the pre-filled pen. Do not use the pre-filled pen if it is dropped without the cap in place. If this happens please contact your doctor or pharmacist. Figure 4

14 Push the pre-filled pen firmly against the skin (see figures 5 and 6) Hold the pre-filled pen comfortably in your hand. DO NOT press the button at this time. You will choose from 2 injection methods. Injecting without pinching the skin is recommended (Figure 5a). However, if you prefer, you may pinch the skin to create a firmer surface for your injection (Figure 5b). Push the open end of the pre-filled pen firmly against the skin at a 90-degree angle until the Safety Sleeve slides fully into the Clear Cover (Figure 6). Figure 5a Figure 5b Position the open end of the pre-filled pen straight onto your skin (90 degrees) Push pre-filled pen firmly against your skin so that the safety sleeve slides up into the clear cover Figure 6 Press button to inject (see figure 7) Continue to push the pre-filled pen firmly against your skin and press the raised part of the button with your fingers or thumb. You will not be able to press in the button unless the pre-filled pen is pushed firmly against your skin and the Safety Sleeve slides into the Clear Cover. Once the button is pressed, it will remain pressed in so you do not need to keep pressure on it.

15 Figure 7 You will hear a loud click sound don t be alarmed. The first click means that the needle has been inserted and the injection has started. You may or may not feel a needle prick at this time. Do not lift the pre-filled pen away from your skin. If you pull the pre-filled pen away from your skin, you may not get your full dose of medicine. Continue to hold until the second click (see figure 8) Continue to hold the pre-filled pen down firmly against your skin until you hear a second click. This usually takes about 3-6 seconds, but it may take up to 15 seconds for you to hear the second click sound. The second click means that the injection is finished and the needle has gone back into the pre-filled pen. If you have hearing problem, count 15 seconds from the time you first press the button and then lift the pre-filled pen from the injection site. Lift the pre-filled pen from the injection site.

16 4. After the injection Figure 8 Use a cotton ball or gauze There may be a small amount of blood or liquid at the injection site. This is normal. You can press a cotton ball or gauze over the injection site for 10 seconds. You may cover the injection site with a small adhesive bandage, if necessary. Do not rub your skin. Check the window a yellow indicator confirms proper administration (see figure 9) The yellow indicator is connected to the plunger of the pre-filled pen. If the yellow indicator is not shown in the window, the plunger has not advanced adequately, and the injection has not occurred. The yellow indicator will fill about half of the viewing window. This is normal. Talk to your doctor or pharmacist if the yellow indicator is not visible in the window or if you suspect that you may not have received a complete dose. Do not administer a second dose without speaking to your doctor. Figure 9

17 Throw the pre-filled pen away (see figure 10) Place your pre-filled pen in a sharps container straight away. Make sure you dispose of the bin as instructed by your doctor or nurse when the container is full. If you feel that something has gone wrong with the injection or if you are not sure, talk to your doctor or pharmacist. Figure 10

Package Leaflet: Information for the user. Simponi 50 mg solution for injection in pre-filled syringe golimumab

Package Leaflet: Information for the user. Simponi 50 mg solution for injection in pre-filled syringe golimumab Package Leaflet: Information for the user Simponi 50 mg solution for injection in pre-filled syringe golimumab Read all of this leaflet carefully before you start using this medicine because it contains

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Aimovig 70 mg solution for injection in pre-filled pen erenumab This medicine is subject to additional monitoring. This will allow quick identification of new

More information

Package leaflet: Information for the user. Tremfya 100 mg solution for injection in pre-filled syringe guselkumab

Package leaflet: Information for the user. Tremfya 100 mg solution for injection in pre-filled syringe guselkumab Package leaflet: Information for the user Tremfya 100 mg solution for injection in pre-filled syringe guselkumab This medicine is subject to additional monitoring. This will allow quick identification

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Package leaflet: Information for the patient Taltz 80 mg solution for injection in pre-filled syringe ixekizumab This medicine is subject to additional monitoring. This will allow quick identification

More information

Package leaflet: Information for the patient. Secukinumab

Package leaflet: Information for the patient. Secukinumab Package leaflet: Information for the patient Cosentyx 150 mg solution for injection in pre-filled pen Secukinumab This medicine is subject to additional monitoring. This will allow quick identification

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Package leaflet: Information for the patient Trulicity 0.75 mg solution for injection in pre-filled pen Trulicity 1.5 mg solution for injection in pre-filled pen dulaglutide This medicine is subject to

More information

Package leaflet: Information for the patient. Secukinumab

Package leaflet: Information for the patient. Secukinumab Package leaflet: Information for the patient Cosentyx 150 mg solution for injection in pre-filled syringe Secukinumab This medicine is subject to additional monitoring. This will allow quick identification

More information

Package leaflet: Information for the user. Repatha 140 mg solution for injection in pre-filled pen evolocumab

Package leaflet: Information for the user. Repatha 140 mg solution for injection in pre-filled pen evolocumab Package leaflet: Information for the user Repatha 140 mg solution for injection in pre-filled pen evolocumab This medicine is subject to additional monitoring. This will allow quick identification of new

More information

Package leaflet: Information for the patient. Olumiant 2 mg film-coated tablets Olumiant 4 mg film-coated tablets Baricitinib

Package leaflet: Information for the patient. Olumiant 2 mg film-coated tablets Olumiant 4 mg film-coated tablets Baricitinib Package leaflet: Information for the patient Olumiant 2 mg film-coated tablets Olumiant 4 mg film-coated tablets Baricitinib This medicine is subject to additional monitoring. This will allow quick identification

More information

SIMPONI Golimumab (rmc) Consumer Medicine Information

SIMPONI Golimumab (rmc) Consumer Medicine Information SIMPONI Golimumab (rmc) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SIMPONI. It does not contain all the available information. It does not take

More information

MEDICATION GUIDE SIMPONI (SIM-po-nee) (golimumab)

MEDICATION GUIDE SIMPONI (SIM-po-nee) (golimumab) MEDICATION GUIDE SIMPONI (SIM-po-nee) (golimumab) Read the Medication Guide that comes with SIMPONI before you start taking it and each time you get a refill. There may be new information. This Medication

More information

TREMFYA (guselkumab) Information for patients

TREMFYA (guselkumab) Information for patients TREMFYA (guselkumab) Information for patients Pre-filled syringe Please read this booklet carefully as it contains important information about TREMFYA, the treatment that your doctor has prescribed to

More information

A STEP-BY-STEP GUIDE FOR HEALTHCARE PROFESSIONALS TO USING THE ENBREL 50MG PRE-FILLED PEN MYCLIC

A STEP-BY-STEP GUIDE FOR HEALTHCARE PROFESSIONALS TO USING THE ENBREL 50MG PRE-FILLED PEN MYCLIC 1. ENBREL (etanercept) SmPC and Patient Information Leaflet. Available at: www.ema.europa.eu. A STEP-BY-STEP GUIDE FOR HEALTHCARE PROFESSIONALS TO USING THE ENBREL 50MG PRE-FILLED PEN MYCLIC Step 1: Preparing

More information

o Your healthcare provider should test you for TB before starting CIMZIA.

o Your healthcare provider should test you for TB before starting CIMZIA. Medication Guide CIMZIA (CIM-zee-uh) (certolizumab pegol) lyophilized powder or solution for subcutaneous use Read the Medication Guide that comes with CIMZIA before you start using it, and before each

More information

Package Leaflet: Information for the user. LUMIGAN 0.3 mg/ml, eye drops, solution, in single-dose container Bimatoprost

Package Leaflet: Information for the user. LUMIGAN 0.3 mg/ml, eye drops, solution, in single-dose container Bimatoprost Package Leaflet: Information for the user LUMIGAN 0.3 mg/ml, eye drops, solution, in single-dose container Bimatoprost Read all of this leaflet carefully before you start using this medicine because it

More information

QUICK TIPS FOR USING THE SENSOREADY PEN

QUICK TIPS FOR USING THE SENSOREADY PEN FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS, ACTIVE PSORIATIC ARTHRITIS, OR ACTIVE ANKYLOSING SPONDYLITIS QUICK TIPS FOR USING THE SENSOREADY PEN INDICATIONS COSENTYX (secukinumab) is a prescription

More information

Package Leaflet: Information for the user

Package Leaflet: Information for the user Package Leaflet: Information for the user ZOSTAVAX Powder and solvent for suspension for injection in a pre-filled syringe shingles (herpes zoster) vaccine (live) Read all of this leaflet carefully before

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. AIM-oh-vig Pr AIMOVIG (erenumab injection)

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. AIM-oh-vig Pr AIMOVIG (erenumab injection) READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION AIM-oh-vig Pr AIMOVIG (erenumab injection) Single-Use Pre-filled SureClick Autoinjector Read this carefully before you

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen exenatide

PACKAGE LEAFLET: INFORMATION FOR THE USER. Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen exenatide PACKAGE LEAFLET: INFORMATION FOR THE USER Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen exenatide Read all of this leaflet carefully before you start

More information

Medication Guide Enbrel (en-brel) (etanercept)

Medication Guide Enbrel (en-brel) (etanercept) Medication Guide Enbrel (en-brel) (etanercept) Read the Medication Guide that comes with Enbrel before you start using it and each time you get a refill. There may be new information. This Medication Guide

More information

REMICADE Infliximab Consumer Medicine Information

REMICADE Infliximab Consumer Medicine Information REMICADE Infliximab Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about It does not contain all the available information. It does not take the place

More information

JUST FOR KIDS SELECTED IMPORTANT SAFETY INFORMATION

JUST FOR KIDS SELECTED IMPORTANT SAFETY INFORMATION JUST FOR KIDS For children ages 6-17 with moderately to severely active Crohn s disease or ulcerative colitis (UC) who haven t responded well to other therapies SELECTED IMPORTANT SAFETY INFORMATION REMICADE

More information

1. What Faslodex is and what it is used for

1. What Faslodex is and what it is used for Package leaflet: Information for the user Faslodex 250 mg solution for injection Fulvestrant Read all of this leaflet carefully before you start using this medicine because it contains important information

More information

Package leaflet: Information for the patient. Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab

Package leaflet: Information for the patient. Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab Package leaflet: Information for the patient Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab This medicine is subject to additional monitoring. This will allow quick identification

More information

Your treatment with XELJANZ

Your treatment with XELJANZ Your treatment with XELJANZ (tofacitinib citrate) THIS BROCHURE HAS BEEN PRODUCED FOR PATIENTS WHO HAVE BEEN PRESCRIBED XELJANZ. BEFORE USING XELJANZ, PLEASE REVIEW THE PACKAGE LEAFLET FOR THIS MEDICINAL

More information

Package leaflet: Information for the patient. Verkazia 1 mg/ml eye drops emulsion ciclosporin

Package leaflet: Information for the patient. Verkazia 1 mg/ml eye drops emulsion ciclosporin Package leaflet: Information for the patient Verkazia 1 mg/ml eye drops emulsion ciclosporin Read all of this leaflet carefully before you start using this medicine because it contains important information

More information

Package leaflet: Information for the user. HBVAXPRO 5 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna)

Package leaflet: Information for the user. HBVAXPRO 5 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna) Package leaflet: Information for the user HBVAXPRO 5 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna) Read all of this leaflet carefully before you or your child is

More information

Package leaflet: Information for the user. PRED MILD STERILE OPHTHALMIC SUSPENSION 0.12% w/v Eye Drops, Suspension Prednisolone Acetate

Package leaflet: Information for the user. PRED MILD STERILE OPHTHALMIC SUSPENSION 0.12% w/v Eye Drops, Suspension Prednisolone Acetate Package leaflet: Information for the user PRED MILD STERILE OPHTHALMIC SUSPENSION 0.12% w/v Eye Drops, Suspension Prednisolone Acetate Read all of this leaflet carefully before you start using this medicine

More information

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe GSK (logo) Package Leaflet: Information for the User Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed). 1440 ELISA Units/1 ml Suspension for Injection in a pre-filled syringe Read all

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. DUKORAL suspension and effervescent granules for oral suspension Cholera vaccine (inactivated, oral)

PACKAGE LEAFLET: INFORMATION FOR THE USER. DUKORAL suspension and effervescent granules for oral suspension Cholera vaccine (inactivated, oral) PACKAGE LEAFLET: INFORMATION FOR THE USER DUKORAL suspension and effervescent granules for oral suspension Cholera vaccine (inactivated, oral) Read all of this leaflet carefully before you start using

More information

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet

More information

Some general information on hepatitis A infection is given at the end of this leaflet.

Some general information on hepatitis A infection is given at the end of this leaflet. Package Leaflet: Information for the User Havrix Monodose Vaccine Suspension for injection in a pre-filled syringe Hepatitis A (inactivated) vaccine (adsorbed) Read all of this leaflet carefully before

More information

Package leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil

Package leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil Package leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil Read all of this leaflet carefully before you start using this medicine because

More information

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase Package leaflet: Information for the user Elaprase 2 mg/ml concentrate for solution for infusion idursulfase This medicine is subject to additional monitoring. This will allow quick identification of new

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Lartruvo 10 mg/ml concentrate for solution for infusion olaratumab This medicine is subject to additional monitoring. This will allow quick identification of new

More information

Package leaflet: Information for the patient. IKERVIS 1 mg/ml, eye drops, emulsion ciclosporin

Package leaflet: Information for the patient. IKERVIS 1 mg/ml, eye drops, emulsion ciclosporin Package leaflet: Information for the patient IKERVIS 1 mg/ml, eye drops, emulsion ciclosporin Read all of this leaflet carefully before you start using this medicine because it contains important information

More information

MEDICATION GUIDE HUMIRA

MEDICATION GUIDE HUMIRA MEDICATION GUIDE HUMIRA (Hu-MARE-ah) (adalimumab) injection Read the Medication Guide that comes with HUMIRA before you start taking it and each time you get a refill. There may be new information. This

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Gardasil, suspension for injection in a pre-filled syringe Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed) Read all of this leaflet

More information

Package leaflet: Information for the user. Resolor 1 mg film-coated tablets Resolor 2 mg film-coated tablets prucalopride

Package leaflet: Information for the user. Resolor 1 mg film-coated tablets Resolor 2 mg film-coated tablets prucalopride Package leaflet: Information for the user Resolor 1 mg film-coated tablets Resolor 2 mg film-coated tablets prucalopride Read all of this leaflet carefully before you start taking this medicine because

More information

Before you take. Tell your doctor if you have any of the conditions mentioned below or if you have ever experienced any of these conditions.

Before you take. Tell your doctor if you have any of the conditions mentioned below or if you have ever experienced any of these conditions. This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. You can report side effects to

More information

Package leaflet: Information for the user. NEVANAC 1 mg/ml eye drops, suspension Nepafenac

Package leaflet: Information for the user. NEVANAC 1 mg/ml eye drops, suspension Nepafenac Package leaflet: Information for the user NEVANAC 1 mg/ml eye drops, suspension Nepafenac Read all of this leaflet carefully before you start using this medicine because it contains important information

More information

Instructions for Use. Welcome!

Instructions for Use. Welcome! Instructions for Use Welcome! The AMJEVITA SureClick autoinjector is a single-use prefilled autoinjector. Consult your doctor if you have any questions about your dose. Your doctor has prescribed AMJEVITA

More information

Package leaflet: Information for the user. HBVAXPRO 40 micrograms, suspension for injection Hepatitis B vaccine (rdna)

Package leaflet: Information for the user. HBVAXPRO 40 micrograms, suspension for injection Hepatitis B vaccine (rdna) Package leaflet: Information for the user HBVAXPRO 40 micrograms, suspension for injection Hepatitis B vaccine (rdna) Read all of this leaflet carefully before you are vaccinated because it contains important

More information

If you have any questions about how Letrozole Tablets works or why this medicine has been prescribed for you, ask your doctor.

If you have any questions about how Letrozole Tablets works or why this medicine has been prescribed for you, ask your doctor. PACKAGE LEAFLET: Information for the user Letrozole 2.5 mg Film-coated Tablets Letrozole Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Package leaflet: Information for the user. Strensiq 100 mg/ml solution for injection (80 mg/0.8 ml) Asfotase alfa

Package leaflet: Information for the user. Strensiq 100 mg/ml solution for injection (80 mg/0.8 ml) Asfotase alfa Package leaflet: Information for the user Strensiq 100 mg/ml solution for injection (80 mg/0.8 ml) Asfotase alfa This medicine is subject to additional monitoring. This will allow quick identification

More information

AIMOVIG TM solution for injection in pre-filled pen erenumab Consumer Medicine Information

AIMOVIG TM solution for injection in pre-filled pen erenumab Consumer Medicine Information This medicine is subject to additional monitoring in Australia. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. You can report side

More information

Sibelium 5 mg Tablets flunarizine

Sibelium 5 mg Tablets flunarizine J-C 2017 Sibelium 5 mg Tablets flunarizine PACKAGE LEAFLET: INFORMATION FOR THE USER Read all of this leaflet carefully before you start taking this medicine because it contains important information for

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Menveo powder and solution for solution for injection Meningococcal Group A, C, W135 and Y conjugate vaccine Read all of this leaflet carefully before you or your

More information

Package leaflet: Information for the user. HBVAXPRO 10 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna)

Package leaflet: Information for the user. HBVAXPRO 10 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna) Package leaflet: Information for the user HBVAXPRO 10 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna) Read all of this leaflet carefully before you are vaccinated

More information

Package Leaflet: Information for the user. NEVANAC 3 mg/ml eye drops, suspension nepafenac

Package Leaflet: Information for the user. NEVANAC 3 mg/ml eye drops, suspension nepafenac Package Leaflet: Information for the user NEVANAC 3 mg/ml eye drops, suspension nepafenac Read all of this leaflet carefully before you start using this medicine because it contains important information

More information

CIMZIA (certolizumab pegol)

CIMZIA (certolizumab pegol) CIMZIA (certolizumab pegol) solution for subcutaneous use Prefilled syringe step-by-step instructions for use INSTRUCTIONS FOR USE Indications: CIMZIA is approved for the treatment of adults with moderate

More information

Package leaflet: Information for the patient. Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets dapagliflozin

Package leaflet: Information for the patient. Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets dapagliflozin Package leaflet: Information for the patient Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets dapagliflozin Read all of this leaflet carefully before you start taking this medicine because

More information

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Kopen Sugar Free 125mg/5ml and 250mg/5ml Powder for Oral Solution Phenoxymethylpenicillin Read all of this leaflet carefully before you start taking this medicine

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Pneumococcal Polysaccharide Vaccine

PACKAGE LEAFLET: INFORMATION FOR THE USER. Pneumococcal Polysaccharide Vaccine PACKAGE LEAFLET: INFORMATION FOR THE USER PNEUMOVAX 23 solution for injection in a vial Pneumococcal Polysaccharide Vaccine For adults and children 2 years and above. Read all of this leaflet carefully

More information

AIMOVIG solution for injection in pre-filled pen

AIMOVIG solution for injection in pre-filled pen This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. You can report side effects to

More information

MEDICATION GUIDE HUMIRA (HU-MARE-AH) (adalimumab)

MEDICATION GUIDE HUMIRA (HU-MARE-AH) (adalimumab) 17.2 Instruction on Injection Technique The first injection should be performed under the supervision of a qualified health care professional. If a patient or caregiver is to administer HUMIRA, he/she

More information

Package leaflet: Information for the user. Neulasta 6 mg solution for injection pegfilgrastim

Package leaflet: Information for the user. Neulasta 6 mg solution for injection pegfilgrastim Package leaflet: Information for the user Neulasta 6 mg solution for injection pegfilgrastim Read all of this leaflet carefully before you start using this medicine because it contains important information

More information

Package leaflet: Information for the patient. Humira 40 mg solution for injection in pre-filled pen adalimumab

Package leaflet: Information for the patient. Humira 40 mg solution for injection in pre-filled pen adalimumab Package leaflet: Information for the patient Humira 40 mg solution for injection in pre-filled pen adalimumab Read all of this leaflet carefully before you start using this medicine because it contains

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Gardasil 9 suspension for injection in a pre-filled syringe Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed) This medicine is subject to additional

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. GRAZAX 75,000 SQ-T oral lyophilisate

PACKAGE LEAFLET: INFORMATION FOR THE USER. GRAZAX 75,000 SQ-T oral lyophilisate PACKAGE LEAFLET: INFORMATION FOR THE USER GRAZAX 75,000 SQ-T oral lyophilisate Standardised allergen extract of grass pollen from Timothy (Phleum pratense) Read all of this leaflet carefully before you

More information

Package leaflet: Information for the user. Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride

Package leaflet: Information for the user. Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride Package leaflet: Information for the user Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride Read all of this leaflet carefully before you start using this medicine because

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin 250 mg/5 ml Oral Suspension fusidic acid Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Package leaflet: Information for the user. Sebivo 600 mg film-coated tablets Telbivudine

Package leaflet: Information for the user. Sebivo 600 mg film-coated tablets Telbivudine Package leaflet: Information for the user Sebivo 600 mg film-coated tablets Telbivudine Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Package leaflet: Information for the user. Seebri Breezhaler 44 micrograms inhalation powder, hard capsules glycopyrronium (as glycopyrronium bromide)

Package leaflet: Information for the user. Seebri Breezhaler 44 micrograms inhalation powder, hard capsules glycopyrronium (as glycopyrronium bromide) Package leaflet: Information for the user Seebri Breezhaler 44 micrograms inhalation powder, hard capsules glycopyrronium (as glycopyrronium bromide) Read all of this leaflet carefully before you start

More information

Package leaflet: Information for the user. GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution, in single-dose container Bimatoprost/timolol

Package leaflet: Information for the user. GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution, in single-dose container Bimatoprost/timolol Package leaflet: Information for the user GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution, in single-dose container Bimatoprost/timolol Read all of this leaflet carefully before you start using this medicine

More information

Package leaflet: Information for the patient XELJANZ 5 mg film-coated tablets tofacitinib

Package leaflet: Information for the patient XELJANZ 5 mg film-coated tablets tofacitinib Package leaflet: Information for the patient XELJANZ 5 mg film-coated tablets tofacitinib This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

More information

Package leaflet: Information for the patient. Onglyza 2.5 mg film-coated tablets Onglyza 5 mg film-coated tablets Saxagliptin

Package leaflet: Information for the patient. Onglyza 2.5 mg film-coated tablets Onglyza 5 mg film-coated tablets Saxagliptin Package leaflet: Information for the patient Onglyza 2.5 mg film-coated tablets Onglyza 5 mg film-coated tablets Saxagliptin Read all of this leaflet carefully before you start taking this medicine because

More information

Package leaflet: Information for the user. Burinex 5 mg Tablets bumetanide

Package leaflet: Information for the user. Burinex 5 mg Tablets bumetanide Package leaflet: Information for the user Burinex 5 mg Tablets bumetanide Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Fucidin 250 mg Tablets sodium fusidate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

More information

Asacolon 400 mg and 800 mg Gastro-resistant Tablets

Asacolon 400 mg and 800 mg Gastro-resistant Tablets PACKAGE LEAFLET: INFORMATION FOR THE USER Asacolon 400 mg and 800 mg Gastro-resistant Tablets Mesalazine Read all of this leaflet carefully before you start taking this medicine because it contains important

More information

Package leaflet: Information for the user. GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution Bimatoprost/timolol

Package leaflet: Information for the user. GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution Bimatoprost/timolol Package leaflet: Information for the user GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution Bimatoprost/timolol Read all of this leaflet carefully before you start using this medicine because it contains

More information

Instructions for Use Neulasta (nu-las-tah) (pegfilgrastim) Injection, for subcutaneous use Single-Dose Prefilled Syringe. Plunger rod Used plunger rod

Instructions for Use Neulasta (nu-las-tah) (pegfilgrastim) Injection, for subcutaneous use Single-Dose Prefilled Syringe. Plunger rod Used plunger rod Instructions for Use Neulasta (nu-las-tah) (pegfilgrastim) Injection, for subcutaneous use Single-Dose Prefilled Syringe Guide to parts Before use After use Plunger rod Used plunger rod Finger grip Label

More information

Instructions for Use Enbrel (en-brel) (etanercept) injection, for subcutaneous use Single-dose Prefilled Syringe

Instructions for Use Enbrel (en-brel) (etanercept) injection, for subcutaneous use Single-dose Prefilled Syringe Instructions for Use Enbrel (en-brel) (etanercept) injection, for subcutaneous use Single-dose Prefilled Syringe How do I prepare and give an injection with Enbrel Single-dose Prefilled Syringe? There

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Onbrez Breezhaler 150 microgram inhalation powder, hard capsules Onbrez Breezhaler 300 microgram inhalation powder, hard capsules Indacaterol Read all of this

More information

Dorzolamide 20 mg/ml Eye Drops, Solution

Dorzolamide 20 mg/ml Eye Drops, Solution PACKAGE LEAFLET: INFORMATION FOR THE USER Dorzolamide 20 mg/ml Eye Drops, Solution (Dorzolamide hydrochloride) Read all of this leaflet carefully before you start using this medicine because it contains

More information

Package leaflet: Information for the patient. Orgalutran 0.25 mg/0.5 ml solution for injection Ganirelix

Package leaflet: Information for the patient. Orgalutran 0.25 mg/0.5 ml solution for injection Ganirelix Package leaflet: Information for the patient Orgalutran 0.25 mg/0.5 ml solution for injection Ganirelix Read all of this leaflet carefully before you start using this medicine because it contains important

More information

Package leaflet: Information for the user. Pelmeg 6 mg solution for injection in pre-filled syringe Pegfilgrastim

Package leaflet: Information for the user. Pelmeg 6 mg solution for injection in pre-filled syringe Pegfilgrastim Package leaflet: Information for the user Pelmeg 6 mg solution for injection in pre-filled syringe Pegfilgrastim This medicinal product is subject to additional monitoring. This will allow quick identification

More information

Package leaflet: Information for the User Clarityn 1 mg/ml syrup Loratadine

Package leaflet: Information for the User Clarityn 1 mg/ml syrup Loratadine Package leaflet: Information for the User Clarityn 1 mg/ml syrup Loratadine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Always

More information

Golimumab (Simponi ) Therapy

Golimumab (Simponi ) Therapy Patient & Family Guide Golimumab (Simponi ) Therapy 2016 www.nshealth.ca Golimumab (Simponi ) Therapy Your healthcare provider feels that treatment with golimumab may be helpful in managing your inflammatory

More information

Package leaflet: Information for the user. Portrazza 800 mg concentrate for solution for infusion necitumumab

Package leaflet: Information for the user. Portrazza 800 mg concentrate for solution for infusion necitumumab Package leaflet: Information for the user Portrazza 800 mg concentrate for solution for infusion necitumumab This medicine is subject to additional monitoring. This will allow quick identification of new

More information

TYPHIM Vi, Solution for injection

TYPHIM Vi, Solution for injection PACKAGE LEAFLET: INFORMATION FOR THE USER TYPHIM Vi, Solution for injection Purified Vi Capsular Polysaccharide of Salmonella typhi (Ty 2 Strain). Read all of this leaflet carefully before you are vaccinated

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Package leaflet: Information for the patient Parsabiv 2.5 mg solution for injection Parsabiv 5 mg solution for injection Parsabiv 10 mg solution for injection etelcalcetide This medicine is subject to

More information

PATIENT INFORMATION. ORENCIA (oh-ren-see-ah) (abatacept) Lyophilized Powder for Intravenous Infusion

PATIENT INFORMATION. ORENCIA (oh-ren-see-ah) (abatacept) Lyophilized Powder for Intravenous Infusion PATIENT INFORMATION ORENCIA (oh-ren-see-ah) (abatacept) Lyophilized Powder for Intravenous Infusion ORENCIA (oh-ren-see-ah) (abatacept) Injection, Solution for Subcutaneous Administration Read this Patient

More information

IMPORTANT: PLEASE READ. Don t

IMPORTANT: PLEASE READ. Don t PATIENT/CAREGIVER INSTRUCTIONS FOR USE - ORENCIA (ABATACEPT) PREFILLED SYRINGE WITH BD ULTRASAFE PASSIVE TM NEEDLE GUARD WITH FLANGE EXTENDERS Getting started with ORENCIA therapy Did you receive self-injection

More information

Package leaflet: Information for the patient. Histaclar 10 mg Film-coated Tablets loratadine

Package leaflet: Information for the patient. Histaclar 10 mg Film-coated Tablets loratadine Package leaflet: Information for the patient Histaclar 10 mg Film-coated Tablets loratadine Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Zofran syrup contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.

Zofran syrup contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics. Package Leaflet: Information for the User Zofran 4 mg/5 ml Syrup Ondansetron Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

More information

Package Leaflet: Information for the user. Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed)

Package Leaflet: Information for the user. Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed) Package Leaflet: Information for the user Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed) Read all of this leaflet carefully before you or your

More information

1 What Engerix B is and what it is used for

1 What Engerix B is and what it is used for Package leaflet: Information for the user ENGERIX B 20 micrograms/1 ml, suspension for injection Hepatitis B (rdna) vaccine (adsorbed) (HBV) Read all of this leaflet carefully before you start receiving

More information

PRED FORTE 1% w/v Eye Drops, Suspension Prednisolone acetate

PRED FORTE 1% w/v Eye Drops, Suspension Prednisolone acetate Package leaflet: Information for the user PRED FORTE 1% w/v Eye Drops, Suspension Prednisolone acetate Read all of this leaflet carefully before you start using this medicine because it contains important

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PART III: PATIENT MEDICATION INFORMATION. ixekizumab

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PART III: PATIENT MEDICATION INFORMATION. ixekizumab READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PART III: PATIENT MEDICATION INFORMATION Pr TALTZ ixekizumab www.lilly.ca Lilly Read this carefully before you start taking TALTZ and each time you

More information

Package leaflet: Information for the patient. Loratadine 10 mg Tablets (loratadine)

Package leaflet: Information for the patient. Loratadine 10 mg Tablets (loratadine) Package leaflet: Information for the patient Loratadine 10 mg Tablets (loratadine) Read all of this leaflet carefully before you start taking this medicine because it contains important information for

More information

Package leaflet: Information for the patient. Bumetanide 1 mg and 5 mg Tablets (bumetanide)

Package leaflet: Information for the patient. Bumetanide 1 mg and 5 mg Tablets (bumetanide) Package leaflet: Information for the patient Bumetanide 1 mg and 5 mg Tablets (bumetanide) Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Turbohaler budesonide. 1. What Pulmicort Turbohaler is and what it is used for

PACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Turbohaler budesonide. 1. What Pulmicort Turbohaler is and what it is used for PACKAGE LEAFLET: INFORMATION FOR THE USER Pulmicort Turbohaler budesonide Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again. If

More information

Package leaflet: Information for the patient. Humira 20 mg solution for injection in pre-filled syringe adalimumab

Package leaflet: Information for the patient. Humira 20 mg solution for injection in pre-filled syringe adalimumab Package leaflet: Information for the patient Humira 20 mg solution for injection in pre-filled syringe adalimumab Read all of this leaflet carefully before your child starts using this medicine because

More information

Package leaflet: Information for the patient. Zerbaxa 1 g / 0.5 g powder for concentrate for solution for infusion ceftolozane / tazobactam

Package leaflet: Information for the patient. Zerbaxa 1 g / 0.5 g powder for concentrate for solution for infusion ceftolozane / tazobactam Package leaflet: Information for the patient Zerbaxa 1 g / 0.5 g powder for concentrate for solution for infusion ceftolozane / tazobactam This medicine is subject to additional monitoring. This will allow

More information

Package leaflet: Information for the user

Package leaflet: Information for the user CSL Behring Package leaflet: Information for the user Alburex 5, 50 g/l, solution for infusion & Alburex 20, 200 g/l, solution for infusion Human albumin Read all of this leaflet carefully before you are

More information

Pravat 40 mg tablets. Pravastatin sodium

Pravat 40 mg tablets. Pravastatin sodium Package leaflet: Information for the patient Pravat 10 mg tablets Pravat 20 mg tablets Pravat 40 mg tablets Pravastatin sodium Read all of this leaflet carefully before you start taking this medicine because

More information